What would change this recommendation
Nothing found here would turn this into a yes, and that deserves stating rather than leaving a door open the arithmetic does not support.
The recommendation is a no to scaled entry against these targets. Nothing found here would make it a yes, and that deserves stating rather than leaving a door open the arithmetic does not support.
Evidence that the private-label merchant share is materially above 20%, that the module contestable share is above 25%, or a cartridge volume on the scale of the injector segment would each raise 2031 and 2032 revenue. Sized against the margins used here they reduce the loss and do not close it.
None of them would change the verdict on the four criteria, and it is worth being exact about why. The 2029 revenue bar fails because nothing can ship until the certificate exists and a customer has qualified the plant, which is a calendar of about 21 months at best from a standing start. A larger market does not shorten it. The margin bar fails because the whole merchant tier earns about 12% at its best operator. Only two things would change the verdict itself: an acquisition that removes the certificate from the critical path, which affects the calendar rather than the market, or a decision to participate at the device and reimbursement stages, which the brief rules out.
A target acquisition that holds a live certificate, qualified customer status and volume-capable manufacturing at $30M or more of revenue, available at a price MERIDIAN will pay. That removes the calendar constraint, which is the single largest cause of the 2029 miss.
A revision of the targets themselves. This is the most likely path to a yes, and it deserves saying directly. A medical business reaching about $165M of revenue by 2032 at a negative operating margin, diversifying away from a concentrated smartphone customer base, is a defensible thing to build. It is not what the four criteria describe. If leadership's real objective is revenue diversification rather than margin expansion, the criteria are measuring the wrong thing and should be reset before the decision rather than after it.
What would make the no firmer: a certification timeline quote beyond 18 months, or private-label quotations below the modeled price points.
Section added · The brief sets four numeric bars and a decision deadline. The conditions under which the answer flips are what leadership needs in order to act on a call rather than merely receive one.